AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the transaction, the vice president now directly owns 1,780 shares in the company, valued at $180,242.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Sukumar Nagendran also recently made the following trade(s):

  • On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $97.25, for a total transaction of $173,105.00.
  • On Friday, September 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $93.25, for a total transaction of $165,985.00.

AveXis, Inc. (AVXS) traded up $4.61 on Friday, reaching $104.53. 321,612 shares of the company’s stock were exchanged, compared to its average volume of 323,659.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.10). During the same quarter in the prior year, the firm earned ($0.68) EPS. analysts predict that AveXis, Inc. will post -5.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/sukumar-nagendran-sells-1780-shares-of-avexis-inc-avxs-stock.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in AveXis in the third quarter valued at $116,000. Botty Investors LLC acquired a new stake in shares of AveXis in the second quarter valued at about $123,000. Ameritas Investment Partners Inc. grew its position in shares of AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the period. Deschutes Portfolio Strategy LLC acquired a new stake in shares of AveXis in the third quarter valued at about $203,000. Finally, Seven Bridges Advisors LLC grew its position in shares of AveXis by 49.4% in the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock valued at $210,000 after purchasing an additional 846 shares during the period. 94.71% of the stock is owned by institutional investors.

AVXS has been the topic of a number of recent research reports. BMO Capital Markets reiterated a “buy” rating and set a $123.00 price objective on shares of AveXis in a research note on Friday, August 11th. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Morgan Stanley reiterated an “overweight” rating and set a $118.00 price objective on shares of AveXis in a research note on Wednesday, August 9th. Wells Fargo & Company reiterated an “outperform” rating and set a $134.00 price objective (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Finally, Evercore ISI began coverage on shares of AveXis in a research note on Wednesday, August 16th. They set an “outperform” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $107.78.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.